Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||TRAIL-R3 (aa 1-280) - hIgGhc fusion protein.|
|Storage buffer||PBS, pH 7.4|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
TRAIL-R3 (CD263, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
antagonist decoy receptor for TRAIL/Apo-2L; CD263; cytotoxic TRAIL receptor-3; DCR1; decoy receptor 1; decoy TRAIL receptor without death domain; LIT; lymphocyte inhibitor of TRAIL; MGC149501; MGC149502; TNF-related apoptosis-inducing ligand receptor 3; TRAILR3; TRID; tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain
CD263; DCR1; DCR1-TNFR; LIT; TNFRSF10C; TRAIL-R3; TRAILR3; TRID; UNQ321/PRO366